<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1050">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785300</url>
  </required_header>
  <id_info>
    <org_study_id>19-003394</org_study_id>
    <nct_id>NCT04785300</nct_id>
  </id_info>
  <brief_title>ALSENLITE: Senolytics for Alzheimer's Disease</brief_title>
  <official_title>ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James L. Kirkland, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety and feasibility of using Dasatinib and&#xD;
      Quercetin together in subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The underlying processes driving chronic neurodegeneration in Alzheimer's disease (AD) and&#xD;
      related neurodegenerative disorders are largely unknown. Aging is the major risk factor for&#xD;
      AD. Moreover, individuals with AD suffer from significantly more co-morbid conditions than&#xD;
      demographically matched older adults. This study is an open-label pilot study of intermittent&#xD;
      administration of the senolytic drug regimen Dasatinib (D) + Quercetin (Q) in symptomatic&#xD;
      adults over 55 with clinical diagnosis of probable Alzheimer's Disease and Alzheimer's&#xD;
      biomarker positivity by tau-PET.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 6, 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of 11 week of intermittent D+Q treatment</measure>
    <time_frame>11 weeks</time_frame>
    <description>Number of participants to experience adverse events/serious adverse events and hypersensitivity reactions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Dasatinib plus Quercetin Treatment Goup</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with MCI or Alzheimer's disease will take Dasatinib and Quercetin by mouth at the same times for 2 days out of every 15 days for 6 cycles lasting for a total of 77 days (12 concurrent doses of each agent).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>100 mg capsule daily for 2 consecutive days administered orally every 15 days (2 days on drug, 13 days off) for 6 cycles</description>
    <arm_group_label>Dasatinib plus Quercetin Treatment Goup</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quercetin</intervention_name>
    <description>Four 250 capsules once daily (total daily dosage 1000 mg) administered orally for 2 consecutive days every 15 days (2 days on drug, 13 days off) for 6 cycles</description>
    <arm_group_label>Dasatinib plus Quercetin Treatment Goup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women of age 55 years and older at the time of enrollment&#xD;
&#xD;
          2. Clinical diagnosis of symptomatic probable AD (MMSE 26 to 15 or Short Test of Mental&#xD;
             Status 31 to 15 inclusive and/or Clinical Dementia Rating Scale/CDR = 0.5 to 2,&#xD;
             inclusive)&#xD;
&#xD;
          3. Not on cholinesterase inhibitors or memantine; or if on cholinesterase inhibitors&#xD;
             and/or memantine, on a stable dose for at least three months&#xD;
&#xD;
          4. Body Mass Index (BMI) within range of 19 - 50 kg/ m2&#xD;
&#xD;
          5. Participants must be accompanied by a LAR designated to sign informed consent and to&#xD;
             provide study partner reported outcomes at all visits&#xD;
&#xD;
          6. Participants must have no plans to travel over the ~3 months between Visits 3 and 14&#xD;
             that interfere with study visits&#xD;
&#xD;
          7. Tau positivity by brain PET imaging&#xD;
&#xD;
          8. Adequate blood counts i.e. platelets &gt; 50,000 per microliter; HB &gt; 9/dL, and ANC &gt;&#xD;
             1000 per microliter&#xD;
&#xD;
          9. Availability and consent from a LAR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unwilling or unable to give informed consent&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. QTc &gt; 450 msec on baseline ECG&#xD;
&#xD;
          4. MRI contraindications&#xD;
&#xD;
          5. Presence of uncontrolled psychiatric disorder (as per clinical judgment)&#xD;
&#xD;
          6. Presence of uncontrolled systemic lupus erythematosus (as per clinical judgment)&#xD;
&#xD;
          7. Substance or alcohol abuse (current alcohol use &gt; 3 alcoholic beverage/day or &gt; 21 per&#xD;
             week and as per clinical judgment)&#xD;
&#xD;
          8. Hearing, vision, or motor deficits despite corrective devices (as per clinical&#xD;
             judgment)&#xD;
&#xD;
          9. Myocardial infarction, angina, stroke, or transient ischemic attack in the past 6&#xD;
             months&#xD;
&#xD;
         10. Chronic heart failure (as per clinical judgment)&#xD;
&#xD;
         11. Neurologic, musculoskeletal, or other condition that limits subject's ability to&#xD;
             complete study physical assessments (as per clinical judgment)&#xD;
&#xD;
         12. Positive SARS-CoV-2 test within 30 days prior to enrollment&#xD;
&#xD;
         13. AST/ALT &gt; 2.5x upper limit normal&#xD;
&#xD;
         14. Presence of significant liver disease with total bilirubin &gt; 2X upper limit or as per&#xD;
             clinical judgment&#xD;
&#xD;
         15. Inability to tolerate oral medication (as per clinical judgment)&#xD;
&#xD;
         16. Abnormality in any of the screening laboratory studies (see section 6.21.2) or as per&#xD;
             clinical judgment&#xD;
&#xD;
         17. Malabsorption (as per clinical judgment)&#xD;
&#xD;
         18. Known human immunodeficiency virus infection (as per clinical judgment)&#xD;
&#xD;
         19. Known active hepatitis B or C infection&#xD;
&#xD;
         20. Invasive fungal or viral infection (as per clinical judgment)&#xD;
&#xD;
         21. Known hypersensitivity or allergy to D or Q&#xD;
&#xD;
         22. Uncontrolled pleural/pericardial effusions or ascites (as per clinical judgment)&#xD;
&#xD;
         23. New/active invasive cancer except non-melanoma skin cancers&#xD;
&#xD;
         24. Inability to tolerate oral medications (as per clinical judgment)&#xD;
&#xD;
         25. Currently taking AND unable to safely hold any of the medications listed in Appendix 1&#xD;
             during the days IP is administered and for 36 hours after IP administration.&#xD;
&#xD;
         26. Uncontrolled diabetes (defined as HbA1c &gt; 7% or as per clinical judgment).&#xD;
&#xD;
         27. Gastric bypass/reduction&#xD;
&#xD;
         28. Crohn's disease&#xD;
&#xD;
         29. Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase&#xD;
             or ESR) (as per clinical judgment)&#xD;
&#xD;
         30. eGFR &lt; 10 ml/ min/ 1.73 m2&#xD;
&#xD;
         31. Creatinine clearance &lt; 60 mL/min/1.73 m2&#xD;
&#xD;
         32. Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low&#xD;
             molecular weight heparin, factor Xa inhibitors, etc.)&#xD;
&#xD;
         33. On antiplatelet agents (e.g., full dose Aspirin, Clopidogrel etc.). Baby aspirin (81&#xD;
             mg), if absolutely necessary from cardiac perspective, will be allowed&#xD;
&#xD;
         34. Presence of any condition that the Investigator believes would put the subject at risk&#xD;
             or would preclude the patient from successfully completing all aspects of the trial&#xD;
&#xD;
        Involvement of special vulnerable populations: We will not involve special vulnerable&#xD;
        populations, such as fetuses, neonates, pregnant women, children, prisoners,&#xD;
        institutionalized individuals, or others who may be considered vulnerable populations&#xD;
        except for patients with dementia. Therefore, availability and consent from a LAR is an&#xD;
        inclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald C Petersen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>September 9, 2022</last_update_submitted>
  <last_update_submitted_qc>September 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>James L. Kirkland, MD, PhD</investigator_full_name>
    <investigator_title>Regulatory Sponsor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

